Sponsored Lunch Talk | 17 July 2025

Lunch Talk Sponsored by:

Title: Connecting the Dots: LATUDA at the Intersection of Metabolism, Cognition, and Schizophrenia Symptom Control Speaker: Assoc. Prof Dr. Pongsatorn Paholpak (Psychiatrist, Khon Kean University Thailand)

Abstract

Treating schizophrenia effectively requires more than just controlling positive symptoms-clinicians must also consider the broader impact on patients' cognitive function and metabolic health, which significantly influence long-term outcomes, functional recovery, and quality of life. However, many antipsychotic treatments are associated with metabolic side effects and cognitive dulling, complicating disease management.
This presentation explores how LATUDA (Lurasidone) stands at the intersection of this complex triangle, offering a balanced approach to schizophrenia treatment. With a favourable metabolic profile, minimal impact on weight and lipids, and evidence supporting cognitive benefit, LATUDA helps clinicians "connect the dots" between symptom control, cognitive preservation, and metabolic safety. The session will also highlight clinical data, comparative insights with other antipsychotics, and the implications for holistic, recovery-oriented care in schizophrenia.
Lastly, this is followed by a case study sharing of LATUDA use in schizophrenia patient with metabolic and cognition concern (younger patient) and how LATUDA helps this patient to connect the dots of metabolic, cognition and schizophrenia symptoms control.